The effect of an apparent change to a branded or generic medication on drug effectiveness and side effects

Psychosomatic Medicine

Volumn 75, Issue 1, 2013, Pages 90-96

  Faasse, Kate ^a   Cundy, Tim ^a   Gamble, Greg ^a   Petrie, Keith J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

expectations; generic medication; nocebo; placebo; side effects

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NOVAPROL; PLACEBO; PROPRANOLOL; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG LABELING; DRUG SAFETY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TABLET; XEROSTOMIA;

EID: 84872295361     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e3182738826     Document Type: Article

References (45)

1. Stewart-Williams S, Podd J. The placebo effect: Dissolving the expectancy versus conditioning debate. Psychol Bull 2004;130:324-40.
2. Klosterhalfen S, Enck P. Neurophysiology and psychobiology of the placebo response. Curr Opin Psychiatry 2008;21:189-95.
3. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7.
4. Edwards R, Graedon J, Graedon T. Placebo harm. Drug Saf 2010; 33:439-41.
5. Hahn RA. The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med 1997;26:607-11.
6. Colloca L, Miller FG. Role of expectations in health. Curr Opin Psychiatry 2011;24:149-55.
7. Stewart-Williams S. The placebo puzzle: putting together the pieces. Health Psychol 2004;23:198-206.
8. Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 2012;307:567-8.
9. Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med 2011;73:598-603.
10. van Laarhoven AIM, VogelaarML,Wilder-Smith OH, van Riel PLCM, van de Kerkhof PCM, Kraaimaat FW, Evers AWM. Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain 2011;152:1486-94.
11. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE 2010;5:e15591.
12. Moerman DE. Cultural variations in the placebo effect: ulcers, anxiety, and blood pressure. Med Anthropol Q 2000;14:51-72.
13. Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side-effects after placebo treatment in headaches. Cephalalgia 2011;31:550-61.
14. Mitsikostas DD, Chalarakis NG, Mantonakis LI, Delicha E-M, Sfikakis PP. Nocebo in fibromyalgia: meta-analysis of placebo controlled clinical trials and implications for practice. Eur J Neurol 2012;19:672-80.
15. Iosifescu A, Halm EA, McGinn T, Siu AL, Federman AD. Beliefs about generic drugs among elderly adults in hospital-based primary care practices. Patient Educ Couns 2008;73:377-83.
16. Ameri MN, Whittaker C, Tucker A, Yaqoob M, Johnston A. A survey to determine the views of renal transplant patients on generic substitution in the UK. Transpl Int 2011;24:770-9.
17. Himmel W, Simmenroth-Nayda A, Niebling W, Ledig T, Jansen R-D, Kochen MM, Gleiter CH, Hummers-Pradier E. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther 2005;43:472-9.
18. Figueiras MJ, Cortes MA, Marcelino D, Weinman J. Lay views about medicines: the influence of the illness label for the use of generic versus brand. Psychol Health 2010;25:1121-8.
19. Kjoenniksen I, Lindbaek M, Granas AG. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006;28:284-9.
20. Brennan TA, Lee TH. Allergic to generics. Ann Intern Med 2004;141:126-30.
21. Kobayashi E, Nobunori S, Ueda S. Community pharmacists' perspectives on generic substitution in Japan. J Public Health 2011;19:249-56.
22. Heikkila R, Mantyselka P, Hartikainen-Herranen K, Ahonen R. Consumers' and physicians' opinions of and experiences with generic substitution during the first year in Finland. Health Policy 2007;82:366-74.
23. Hassali MA, Kong DCM, Stewart K. A comparison between senior medical students' and pharmacy pre-registrants' knowledge and perceptions of generic medicines. Med Educ 2007;41:703-10.
24. Howland RH. Are generic medications safe and effective? J Psychol Nurs 2010;48:13-6.
25. Chandler J, Owen M. Pharmaceuticals: the new brand arena. Int J Market Res 2002;44:385-404.
26. Branthwaite A, Cooper P. Analgesic effects of branding in treatment of headaches. BMJ 1981;282:1576-8.
27. Steinman MA, Chren M-M, Landefeld S. What's in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med 2007;22:645-8.
28. Shiv B, Carmon Z, Ariely D. Placebo effects of marketing actions: consumers get what they pay for. J Mark Res 2005;152:383-93.
29. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA 2008;299:1016-7.
30. Phillips B, Aziz F, O'Regan CP, Roberts C, Rudolph AE, Morant S. Switching statins: the impact on patient outcomes. Br J Cardiol 2007; 14:280-5.
31. Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009;30:213-21.
32. Johnston A. Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Curr Med Res Opin 2010;26:871-8.
33. Weissenfeld J, Stock S, Lungen M, Gerber A. The nocebo effect: a reason for patients' non-adherence to generic substitution? Pharmazie 2009;65: 451-6.
34. Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille M-H, Latremouille-Viau D, Lefebvre P, Helmers SL. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 2010;74:1566-74.
35. Faasse K, Cundy T, Petrie KJ. Thyroxine: anatomy of a health scare. BMJ 2009;339:b5613.
36. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Speilberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992;31:301-6.
37. Eriksen HR, Ihlebaek C, Ursin H. A scoring system for subjective health complaints (SHC). Scand J Public Health 1999;27:63-72.
38. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002;2:8.
39. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6.
40. Vickers A, Altman D. Analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123-4.
41. Persson LO, Sjoberg L. Mood and somatic symptoms. J Psychosom Res 1987;31:499-511.
42. Piccinelli M, Simon G. Gender and cross-cultural differences in somatic symptoms associated with emotional distress: an international study in primary care. Psychol Med 1997;27:433-44.
43. Lambert-Pandraud R, Gilles L. Impact of age on brand choice. In: Drolet A, Schwarz N, Yoon C, editors. The Aging Consumer: Perspectives From Psychology and Economics. New York: Routledge/Taylor & Francis Group; 2010:191-208.
44. Eidelman S, Pattershall J, Crandall CS. Longer is better. J Exp Soc Psychol 2010;46:993-8.
45. Ammassari A, Murri R, Pezzotti P, Trotta M, Ravasio L, De Longis P, Lo Caputo S, Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo C, Lichtner M, Rezza G, Monforte A, Ippolito G, d'Arminio Moroni M, Wu A, Antinori A, AdiICONA Study Group. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-9.